Disease Roundup: Genomic Medicine Candidates for...
Jul. 20, 2022
Relevant Interviews, Disease and Trial Updates and Stock-Markets News posted by CRISPR Medicine News.
Check also Companies to Follow in 2022 and CMN Markets for the latest stock and market trends.
Always stay updated with the free CMN Newsletter.
Sanofi
Main (gene editing) focus: Blood diseases
Company stage: Commercial
Diseases: Sickle cell disease, beta-thalassemia
Genome editing tool: Zinc finger nucleases (ZFNs)
Funding stage: Public (NASDAQ:SNY)
Location: Paris, France
Website: https://www.sanofi.com/
Pipeline: https://www.sanofi.com/en/science-and-innovation/research-and-development/rd-pipeline
Partners: Sangamo Therapeutics
Sanofi is a large pharmaceutical company that is primarily involved in the gene-editing space through its collaboration with Sangamo Therapeutics. Two programmes are being developed under the collaboration: SAR445136 and ST-400 for sikcle cell disease and beta thalassemia, respectively. Both programmes are currently being tested in Phase 1/2 clinical trials, with postive preliminary results to date.
